Research · Sep 3, 2026
[VEEV] Veeva Systems Thesis 2026: Vault CRM Migration Removes Salesforce Risk
Veeva Systems (VEEV) FY26 (Jan 2026) revenue $3.195B (+16.3%); gross margin 75.5% (+100bp); GAAP op income $916.4M (+32.5%, margin 28.7%); non-GAAP op income $1.434B (+24.5%); GAAP net income $908.9M (+27.3%); EPS $5.44 (+25.9%); FCF $1.386B (+29.6%); cash $1.421B; total debt $96M. First-ever share buybacks: $169.9M. Vault CRM migration: 140+ live bulk customers; all top-20 customers committed; migration risk largely resolved. Crossix (commercial data analytics) growing 30%+ YoY. IQVIA lawsuit resolved (Q2 FY26) — unlocks commercial cloud data integration. Veeva AI across product suite (eTMF Bot, CRM Voice Control). $6B FY30 revenue target (17% CAGR from FY26). Horizontal CRM initiative (non-life-sciences) announced. Life sciences cloud: Vault Clinical (eTMF, CTMS, LIMS), Vault Quality, Vault Regulatory, Safety — all with FDA/EMA validation switching costs. Net revenue retention >100%. Risks: Vault CRM attrition from 6 customers, Salesforce CRM competition, pharma R&D cuts, biotech funding, Crossix data privacy, horizontal CRM execution.